New drug combo shows promise for aggressive stomach cancer
NCT ID NCT04661150
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 29 times
Summary
This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy and trastuzumab can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants will receive either the standard treatment or the standard plus atezolizumab before and after surgery. The main goal is to see if the combination leads to a complete disappearance of cancer cells in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
First Hospital of China Medical University
Shenyang, 110001, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Liaoning Provincial Cancer Hospital
Shengyang, 110042, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, 510515, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjing, 300060, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.